MRCP UK EXAMINATIONS

Detailed explanation-1: -After initiation of the DOAC the patient must be seen within 4 weeks for an initial review3 and then at least once more within the 6 months following initiation. Table 1. P-gp: P-glycoprotein inhibitor; CrCl: Creatinine Clearance; Serum Cr: Serum Creatinine; GORD: gastro oesophageal reflux disease.

Detailed explanation-2: -First, patients who do not have hemodynamic decompensation can safely transition from parenteral heparin to an oral anticoagulant after just 72 hours. Second, transition from parenteral heparin to oral dabigatran anticoagulation can safely occur without a full 5-to 10-day lead-in period.

Detailed explanation-3: -Conclusions. The combined use of Apixaban with heparin is high-performing and safe in the treatment of CVT. The changes of D-D and FIB levels during the treatment are strongly linked to the therapeutic effect, which can be used as plausible evaluation indexes for the efficacy of CVT.

Detailed explanation-4: -LMWHs have been the treatment of choice for cancer associated VTE. DOACs are more effective than LMWHs to prevent recurrent VTE in cancer patients. DOACs are associated with a higher risk of major bleeding compared to LMWHs. Effectiveness and safety may reflect better compliance with DOACs compared to LMWHs.